AR060411A1 - A PHARMACEUTICAL COMPOSITION USED IN THE TREATMENT OR PREVENTION OF A PULMONARY DISEASE AND USE OF N-SULFOETILNICOTINAMIDA IN THE TREATMENT OR PREVENTION OF SUCH DISEASE - Google Patents

A PHARMACEUTICAL COMPOSITION USED IN THE TREATMENT OR PREVENTION OF A PULMONARY DISEASE AND USE OF N-SULFOETILNICOTINAMIDA IN THE TREATMENT OR PREVENTION OF SUCH DISEASE

Info

Publication number
AR060411A1
AR060411A1 ARP070101507A ARP070101507A AR060411A1 AR 060411 A1 AR060411 A1 AR 060411A1 AR P070101507 A ARP070101507 A AR P070101507A AR P070101507 A ARP070101507 A AR P070101507A AR 060411 A1 AR060411 A1 AR 060411A1
Authority
AR
Argentina
Prior art keywords
prevention
treatment
disease
pharmaceutical composition
sulfoetilnicotinamida
Prior art date
Application number
ARP070101507A
Other languages
Spanish (es)
Inventor
Moises Gabriel Zeitune
Ruben Martin Laguens
Original Assignee
Creactivar S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Creactivar S A filed Critical Creactivar S A
Priority to ARP070101507A priority Critical patent/AR060411A1/en
Priority to PCT/MX2008/000048 priority patent/WO2008123758A1/en
Publication of AR060411A1 publication Critical patent/AR060411A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente se refiere a una composicion farmacéutica que comprende al compuesto N-sulfoetilnicotinamida (NESA) o un derivado farmacéuticamente aceptable del mismo. La composicion es utilizable en el tratamiento o prevencion de una enfermedad pulmonar. En particular, la composicion comprende entre alrededor de 7 mg y alrededor de 1 g de N-sulfoetilnicotinamida (NESA) o un derivado farmacéuticamente aceptable de la misma. De preferencia, la composicion comprende entre alrededor de 140 mg y alrededor de 800 mg de N-sulfoetilnicotinamida (NESA) o un derivado farmacéuticamente aceptable de la misma. Más preferentemente aun, la composicion comprende entre alrededor de 250 mg y alrededor de 500 mg de N-sulfoetilnicotinamida (NESA) o un derivado farmacéuticamente aceptable de la misma.This refers to a pharmaceutical composition comprising the compound N-sulfoethylnicotinamide (NESA) or a pharmaceutically acceptable derivative thereof. The composition is usable in the treatment or prevention of a lung disease. In particular, the composition comprises between about 7 mg and about 1 g of N-sulfoethylnicotinamide (NESA) or a pharmaceutically acceptable derivative thereof. Preferably, the composition comprises between about 140 mg and about 800 mg of N-sulfoethylnicotinamide (NESA) or a pharmaceutically acceptable derivative thereof. More preferably, the composition comprises between about 250 mg and about 500 mg of N-sulfoethylnicotinamide (NESA) or a pharmaceutically acceptable derivative thereof.

ARP070101507A 2007-04-10 2007-04-10 A PHARMACEUTICAL COMPOSITION USED IN THE TREATMENT OR PREVENTION OF A PULMONARY DISEASE AND USE OF N-SULFOETILNICOTINAMIDA IN THE TREATMENT OR PREVENTION OF SUCH DISEASE AR060411A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
ARP070101507A AR060411A1 (en) 2007-04-10 2007-04-10 A PHARMACEUTICAL COMPOSITION USED IN THE TREATMENT OR PREVENTION OF A PULMONARY DISEASE AND USE OF N-SULFOETILNICOTINAMIDA IN THE TREATMENT OR PREVENTION OF SUCH DISEASE
PCT/MX2008/000048 WO2008123758A1 (en) 2007-04-10 2008-04-10 Pharmaceutical composition comprising n-sulphoethylnicotinamide useful in treatment or prevention of a pulmonary disease and use of said composition for treatment or prevention of said disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ARP070101507A AR060411A1 (en) 2007-04-10 2007-04-10 A PHARMACEUTICAL COMPOSITION USED IN THE TREATMENT OR PREVENTION OF A PULMONARY DISEASE AND USE OF N-SULFOETILNICOTINAMIDA IN THE TREATMENT OR PREVENTION OF SUCH DISEASE

Publications (1)

Publication Number Publication Date
AR060411A1 true AR060411A1 (en) 2008-06-18

Family

ID=39590599

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070101507A AR060411A1 (en) 2007-04-10 2007-04-10 A PHARMACEUTICAL COMPOSITION USED IN THE TREATMENT OR PREVENTION OF A PULMONARY DISEASE AND USE OF N-SULFOETILNICOTINAMIDA IN THE TREATMENT OR PREVENTION OF SUCH DISEASE

Country Status (2)

Country Link
AR (1) AR060411A1 (en)
WO (1) WO2008123758A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115697318A (en) * 2020-04-02 2023-02-03 炎症药物有限责任公司 Medical active substance

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1408481A (en) * 1973-02-15 1975-10-01 Seperic Beta-pyridyl-carbon-amido-alkane-sulphonic acid salts their preparation and their applications
US5840294A (en) * 1993-03-29 1998-11-24 Queen's University At Kingston Method for treating amyloidosis

Also Published As

Publication number Publication date
WO2008123758A1 (en) 2008-10-16

Similar Documents

Publication Publication Date Title
CL2008003298A1 (en) Solid oral dosage form comprising a) a dual-acting compound in concentration between 4 and 90%, b) a pharmaceutically acceptable excipient; Preparation process; use in the treatment of cardiovascular and / or kidney diseases.
SG158870A1 (en) Bendamustine pharmaceutical compositions for lyophilisation
GT200600163A (en) NEW THERAPEUTIC COMBINATIONS FOR THE TREATMENT OR PREVENTION OF DEPRESSION
CL2007001752A1 (en) Compound 4- [5 (2-amino-ethanesulfonyl) -isoquinolin-7-yl] -phenolo a pharmaceutically acceptable salt or a hydrate or salt thereof; pharmaceutical composition comprising said compound, lyophilized pharmaceutical composition; and use of the compound as antineiplasic and / or antiviral.
CL2008001855A1 (en) Boron-derived condensed cyclic compounds; pharmaceutical composition; and use in the treatment and / or prevention of an infectious disease.
ECSP088974A (en) IMIDAZOL PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF DISEASES RELATED TO THE SYNTHEOSE QUINASA GLYCOGEN (GSK3)
CO6331425A2 (en) COMPOSITIONS THAT INCLUDE N- (3,4-DIFLUORO-2- (2-FLUORO-4-IODOFENILAMINO) 6-METOXIFENIL) -1- (2,3-DIHYDROXIPROXIPROPIL) CICLOPROPAN-1-SULFAMIDA
ES2916604T1 (en) Nrf2 Detection Assays and Related Methods and Compositions
ECSP11010948A (en) INHIBITORS OF PROTEIN CINASE ENZYMES ACTIVATED BY
CY1116931T1 (en) METAXOXIN ORAL PREPARATION
CL2007001992A1 (en) COMPOUNDS DERIVED FROM PYRIMIDILCICLOPENTANOS; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND IN THE TREATMENT OF AN INFLAMMATORY, HYPERPROLIFERANT, CARDIOVASCULAR, NEURODEGE DISEASE
NO20084256L (en) DPP IV inhibitor formulations
NO20074824L (en) Extension of time to disease progression or survival in cancer patients
AR072261A1 (en) PIPERAZIN-PIRAZOLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEMSELVES AND USES OF THE SAME AS ANTICANCERIGEN AGENTS.
AR056800A1 (en) USE OF PDE III INHIBITORS FOR THE TREATMENT OF ASYDOMATIC CARDIAC ISUFFICIENCY (HIDDEN)
CL2010001361A1 (en) Compounds derived from piperidine-carboxamide, renin inhibitors; pharmaceutical composition that includes them; and use in the treatment or prevention of a circulatory disease, hypertension and / or various organic damages attributable to hypertension.
PA8809601A1 (en) ANTI-RETROVIRAL COMBINATION
CL2009000914A1 (en) Compounds derived from 1-cyano-3-pyrrolidinyl-n-substituted-sulfonamides, cathepsin c inhibitors; pharmaceutical composition comprising said compound; and use of the compound for the treatment of a chronic obstructive pulmonary disease.
CL2011000798A1 (en) Use of dabigatran etexilate or a salt thereof to prepare a useful medication for the prevention of stroke in patients suffering from atrial fibrillation.
UA94036C2 (en) Bendamustine pharmaceutical compositions for lyophilisation
AR077125A1 (en) PHARMACEUTICAL COMBINATIONS USEFUL TO TREAT HCV
UY31403A1 (en) "NOVEDOUS DERIVATIVES OF ({((3-Methylphenyl) -2H-TETRAZOL-5-IL) -ETOXI} -4H-1,2,4-TRIAZOL-3-IL), PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND MEDICAL USE OF THE SAME" .
ECSP10010052A (en) GALENIC FORMULATIONS OF ALISQUIRENO AND VALSARTAN
CL2007003643A1 (en) PHARMACEUTICAL COMPOSITION OF AZIMILIDINE THAT INCLUDES 0.5% TO APPROXIMATELY 2.5% (W / W) OF WATER; AND USE FOR THE TREATMENT OF CARDIAC ARRITMIAS.
CL2007001748A1 (en) Compound derived from 2-arylamino-4-aminopyrimidines, c-alpha protein kinase inhibitors; pharmaceutical compositions containing them; and its use to treat or prevent diabetes, cancer, cardiovascular diseases and others.

Legal Events

Date Code Title Description
FB Suspension of granting procedure